Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The oral obesity drug race is heating up. Eli Lilly announced its pill Foundayo has captured over 30% of new U.S. patients in the oral weight-loss market, chipping away at Novo Nordisk's early dominance. Novo's Wegovy pill still leads with an estimated 90% market share, but Lilly is closing the gap — and both companies are betting big on pills to expand the obesity treatment market well beyond current injectable users.
The battle for oral obesity drug dominance is intensifying. Eli Lilly revealed that its once-daily pill Foundayo — approved and launched in the U.S. in April 2026 — has already captured more than 30% of new patients in the oral weight-loss market, narrowing the lead held by Novo Nordisk's Wegovy pill. Novo's CEO had previously estimated the Wegovy pill held roughly 90% of the oral obesity market, but Lilly's momentum is building fast.
Beyond the pill rivalry, Lilly's injectable GLP-1 treatments are also performing strongly. Its Zepbound obesity drug is seeing strong preference in the U.S. government's new Medicare obesity pilot — launched in July — which offers eligible patients weight-loss drugs for just $50/month. About 60–70% of enrollees are new to these treatments entirely, suggesting the program is genuinely expanding access rather than just shifting existing patients.
By the Numbers:
Why it matters: Pills could be the key to unlocking the next wave of obesity treatment adoption — reaching the millions of patients who've avoided injections. With Medicare now subsidizing access and both Lilly and Novo aggressively expanding globally, the oral obesity drug market is poised for significant growth, reshaping how clinicians and payers approach weight management at scale.
